Prestige Consumer Healthcare (PBH) AI Stock Analysis

• Market Cap: $3.06B
• Dividend Yield: N/A
• Average Volume (3M): 457.94K
• Price to Earnings (P/E): 14.6
• Beta (1Y): 0.32
• Revenue Growth: 0.63%
• EPS Growth: 4.23%
• Country: US
• Employees: 600
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 0.95
• Shares Outstanding: 49,214,172
• 10 Day Avg. Volume: 383,447
• 30 Day Avg. Volume: 457,945
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.59
• Enterprise Value/Revenue: 4.36
• Enterprise Value/Gross Profit: 7.76
• Enterprise Value/Ebitda: 13.58
• 1Y Price Target: $80.75
• Price Target Upside: 29.39% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 62 Neutral
• Price Target: $65.00 ▲(4.15% Upside)

Prestige Consumer Healthcare's overall stock score reflects solid financial performance and reasonable valuation, but is tempered by bearish technical indicators and mixed earnings call sentiment. The company's profitability and cash flow are strong, but challenges in revenue growth and supply chain issues present risks. The stock's current technical weakness suggests caution in the short term.

Positive Factors

Cash Flow Generation

Strong cash flow generation indicates effective financial management and provides the company with flexibility for reinvestment and debt reduction.

International Growth

Robust international growth reflects successful market expansion and diversification, reducing reliance on domestic markets and enhancing revenue stability.

Strategic Acquisition

The acquisition of Pillar5 Pharma addresses supply chain issues and enhances production capacity, supporting long-term growth in the eye care segment.

Negative Factors

Revenue Decline

The revenue shortfall indicates challenges in meeting sales targets, which could impact profitability and investor confidence if not addressed.

Supply Chain Issues

Extended supply chain disruptions in the eye care segment can lead to lost sales and customer dissatisfaction, affecting long-term brand loyalty.

Retail Order Volatility

Retail order volatility introduces uncertainty in revenue forecasting, complicating inventory management and financial planning.

Prestige Consumer Healthcare Business Overview & Revenue Model

Company Description

Prestige Consumer Healthcare (PBH) is a leading global company specializing in over-the-counter (OTC) healthcare products. The company operates in various sectors including pain relief, cold and allergy, personal care, and foot care. PBH's core offerings include well-known brands such as TheraGun, Dramamine, and Chloraseptic, among others, which cater to a wide range of consumer health needs.

How the Company Makes Money

PBH generates revenue primarily through the sale of its branded OTC healthcare products in both retail and e-commerce channels. The company leverages its established brand portfolio and extensive distribution network to reach consumers effectively. Key revenue streams include direct sales to major retail chains, pharmacies, and online platforms. Additionally, PBH benefits from partnerships with various retailers for promotional activities and shelf space, which enhance product visibility and sales. The company also invests in marketing and innovation to develop new products and improve existing ones, driving further revenue growth.

Prestige Consumer Healthcare Financial Statement Overview

Summary

Prestige Consumer Healthcare demonstrates solid financial health across income, balance sheet, and cash flow metrics. The company shows consistent revenue growth and strong profitability margins, while maintaining a low leverage position. Cash flow generation is stable, supporting operational and financial flexibility. Overall, the company's financial statements reflect a well-managed business with potential for continued growth and profitability.

Income Statement

Prestige Consumer Healthcare has shown consistent revenue growth, with a 1.1% increase from 2024 to 2025. The gross profit margin remains strong at 55.8% in 2025, reflecting effective cost management. However, the EBIT margin slightly decreased from 30.4% in 2024 to 29.6% in 2025, indicating some pressure on operational efficiency. The net profit margin improved slightly to 18.9% in 2025, highlighting enhanced profitability.

Balance Sheet

The company's financial stability is solid with a low debt-to-equity ratio of 0.03 in 2025, demonstrating effective debt management. The equity ratio is strong at 53.9%, indicating a healthy proportion of equity financing. Return on equity stands at 11.7%, showing reasonable profitability for shareholders. The improvement in equity and reduction in total liabilities over the years reflect a strengthening balance sheet.

Cash Flow

Operating cash flow increased slightly to $251.5 million in 2025, supporting ongoing operations effectively. Free cash flow growth is modest at 1.6% year-over-year, but the free cash flow to net income ratio is robust at 1.13, indicating strong cash generation relative to profits. The stable cash flow trends suggest efficient cash management and operational stability.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.12B	1.14B	1.13B	1.13B	1.09B	943.37M
Gross Profit	629.29M	634.46M	624.45M	625.29M	620.65M	547.47M
EBITDA	359.60M	361.99M	373.86M	14.19M	351.61M	310.38M
Net Income	213.00M	214.60M	209.34M	-82.31M	205.38M	164.68M
Balance Sheet
Total Assets	3.43B	3.40B	3.32B	3.35B	3.67B	3.43B
Cash, Cash Equivalents and Short-Term Investments	139.50M	97.88M	46.47M	58.49M	27.18M	32.30M
Total Debt	1.04B	1.04B	1.14B	1.37B	1.51B	1.51B
Total Liabilities	1.58B	1.57B	1.66B	1.91B	2.09B	2.07B
Stockholders Equity	1.86B	1.83B	1.66B	1.45B	1.58B	1.36B
Cash Flow
Free Cash Flow	267.84M	243.29M	239.38M	221.93M	250.28M	213.36M
Operating Cash Flow	275.75M	251.51M	248.93M	229.72M	259.92M	235.61M
Investing Cash Flow	-17.26M	-17.45M	-20.11M	-11.58M	-256.51M	-22.24M
Financing Cash Flow	-152.84M	-182.07M	-241.01M	-185.85M	-7.57M	-279.42M

Prestige Consumer Healthcare Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 62.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBH, the sentiment is Negative. The current price of 62.41 is below the 20-day moving average (MA) of 62.47, below the 50-day MA of 63.93, and below the 200-day MA of 76.86, indicating a bearish trend. The MACD of -0.51 indicates Negative momentum. The RSI at 46.34 is Neutral, neither overbought nor oversold. The STOCH value of 61.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PBH.

Prestige Consumer Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MCK	―	$99.72B	31.99	―	0.36%	20.35%	11.96%
HSIC	―	$7.74B	20.43	11.18%	―	2.29%	14.98%
CAH	―	$38.46B	25.10	―	1.24%	-1.94%	85.70%
PBH	―	$3.06B	14.64	12.05%	―	0.63%	4.23%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OMI	―	$425.62M	-0.35	-144.11%	―	-17.10%	-2720.40%
GRDN	―	$1.64B	―	-97.70%	―	―	―

Prestige Consumer Healthcare Corporate Events

Prestige Consumer Healthcare’s Cautious Earnings Call Outlook

During the recent earnings call, Prestige Consumer Healthcare expressed a cautious sentiment. Despite strong performances in the International segment and an expansion in gross margin, challenges in the eye care supply chain and retail order volatility have led to a lowered revenue outlook. The acquisition of Pillar5 is a strategic move to address these issues, but the immediate outlook remains cautious.

Prestige Consumer Healthcare’s Q1 Earnings and Strategic Moves

Prestige Consumer Healthcare Inc. is a leading company in the consumer healthcare sector, known for its diverse portfolio of over-the-counter healthcare products, including well-known brands such as Clear Eyes and Monistat, with operations spanning across the U.S., Canada, and international markets.

Prestige Consumer Healthcare Acquires Pillar5 Pharma for Expansion

On August 4, 2025, Prestige Consumer Healthcare Inc. announced a definitive agreement to acquire Pillar5 Pharma Inc., a leading Canadian sterile ophthalmic manufacturer and current supplier of Clear Eyes, from ANJAC SAS for CAD 150 million. This acquisition is part of Prestige’s strategy to expand eye care production capacity and address supply chain challenges, with the transaction expected to close in the third quarter of fiscal 2026. The company also reported a decline in first-quarter fiscal 2026 revenue to $249.5 million due to supply constraints in the eye care category, although international segment growth and improved gross margins were noted. The acquisition of Pillar5 is anticipated to secure long-term supply chain capacity and support Prestige’s growth opportunities, despite a revised revenue outlook for fiscal 2026.

The most recent analyst rating on (PBH) stock is a Hold with a $90.00 price target. To see the full list of analyst forecasts on Prestige Consumer Healthcare stock, see the PBH Stock Forecast page.